Back to Results
First PageMeta Content



July 8, 2015 Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection Primary results from ongoing 52 week ODYSSE
Add to Reading List

Open Document

File Size: 19,23 KB

Share Result on Facebook

City

TARRYTOWN / New York / PARIS / Sendai / /

Company

Genzyme / Bayer HealthCare LLC / AMF / Regeneron Pharmaceuticals Inc. / Sanofi / /

Country

Japan / /

/

Event

Business Partnership / FDA Phase / Company Listing Change / /

IndustryTerm

healthcare / therapeutic solutions / consumer healthcare / science-based biopharmaceutical / therapeutic applications / diabetes solutions / /

MedicalCondition

atopic dermatitis / rheumatoid arthritis / rare inflammatory condition / familial hypercholesterolemia / back pain / asthma / nasopharyngitis / diabetes / cardiovascular disease / high cholesterol / heart attack / eye diseases / hypercholesterolemia / /

MedicalTreatment

investigational therapy / /

Organization

Endocrinologic and Metabolic Drugs Advisory Committee / Teikyo Academic Research Center / United States Securities and Exchange Commission / U.S. Securities and Exchange Commission / Medicare / Japanese Atherosclerosis Society / Japan Atherosclerosis Society / European Medicines Agency / Metabolic Drugs Advisory Committee / U.S. Food and Drug Administration / Global Communications / PCSK9 Development & Launch Unit / European Union / /

Person

Tamio Teramoto / Manisha Narasimhan / Arleen Goldenberg / Jack Cox / /

/

Position

lead investigator / global healthcare leader / Director / Private / /

Product

primary / Praluent® (alirocumab) / Praluent® (alirocumab) Injection / /

ProvinceOrState

New York / /

Technology

therapeutic solutions / SAN / /

URL

http /

SocialTag